



UNITED STATES DEPARTMENT OF COMMERCE  
Patent and Trademark Office  
Address: COMMISSIONER OF PATENTS AND TRADEMARKS  
Washington, D.C. 20231

APPLICATION NUMBER	FILING DATE	FIRST NAMED APPLICANT	ATTORNEY DOCKET NO.
09/461,061	12/15/99	Mc Crae	6056-260

EXAMINER
HOPE ROBINSON

ART UNIT	PAPER NUMBER
1653	26

DATE MAILED:
--------------

### INTERVIEW SUMMARY

All participants (applicant, applicant's representative, PTO personnel):

(1) Hope Robinson

(3) Hilli Khalilian

(2) Christopher Low

(4)

Date of Interview 9/25/03

Type :  Telephonic  Personal (copy is given to  applicant  applicant's representative).

Exhibit shown or demonstration conducted:  Yes  No If yes, brief description: \_\_\_\_\_

Agreement  was reached.  was not reached.

Claim(s) discussed: \_\_\_\_\_

Identification of prior art discussed: Anerswald et al. and Colman et al.

Description of the general nature of what was agreed to if an agreement was reached, or any other comments: Applicant will consider inserting "consisting of" before the formula recited in claim 10 to indicate that nothing can be added to the compound, to obviate the present grounds of rejection.

(A fuller description, if necessary, and a copy of the amendments, if available, which the examiner agreed would render the claims allowable must be attached. Also, where no copy of the amendments which would render the claims allowable is available, a summary thereof must be attached.)

1.  It is not necessary for applicant to provide a separate record of the substance of the interview.

Unless the paragraph above has been checked to indicate to the contrary, A FORMAL WRITTEN RESPONSE TO THE LAST OFFICE ACTION IS NOT WAIVED AND MUST INCLUDE THE SUBSTANCE OF THE INTERVIEW. (See MPEP Section 713.04). If a response to the last Office action has already been filed, APPLICANT IS GIVEN ONE MONTH FROM THIS INTERVIEW DATE TO FILE A STATEMENT OF THE SUBSTANCE OF THE INTERVIEW.

2.  Since the Examiner's interview summary above (including any attachments) reflects a complete response to each of the objections, rejections and requirements that may be present in the last Office action, and since the claims are now allowable, this completed form is considered to fulfill the response requirements of the last Office action. Applicant is not relieved from providing a separate record of the interview unless box 1 above is also checked.

Examiner Note: You must sign this form unless it is an attachment to another form.

FORM PTOL-413 (REV.1-96)

*Christopher S. F. Low*  
CHRISTOPHER S. F. LOW  
SUPERVISORY PATENT EXAMINER  
TECHNOLOGY CENTER 1600



DrinkerBiddle&Reath  
LLP

Suite 1100  
1500 K Street, N.W.  
Washington, D.C. 20005-1209  
p 202-842-8800

FACSIMILE INFORMATION SHEET

TO: Examiner Hope Robinson FROM: Holli Khalilian DIRECT: 202-354-1341  
DATE: September 24, 2003 DOCUMENT NAME: Proposed Issues for the Interview  
NUMBER OF PAGES: INCLUDING COVER 4  
TELEPHONE NUMBER: 703-308-6231 FAX NUMBER: 703-746-5128

IF YOU DO NOT RECEIVE THIS FAX DOCUMENT IN ITS  
ENTIRETY, PLEASE CALL THE OPERATOR AT (202-842-8800)

DB&R FACSIMILE MACHINES

202-842-8465/66

Message:

Client/Matter No.: 147539

Original will not follow

Original will follow via:  Regular Mail  Overnight Delivery  Hand Delivery  Other: \_\_\_\_\_

The pages which follow are confidential and/or privileged. They are intended solely for the person to whom this cover sheet is addressed. Any review, reproduction or retransmission of such material by any person other than such addressee is unauthorized. If this cover sheet and the pages which follow have been received at your location in error, please notify the operator by telephone (collect) at the number set forth above and return the material U.S. First-Class Mail without inspection. We will reimburse your postage. Thank you for your cooperation.

NS

**PATENT****IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re: Patent application of : Attorney Docket No.: 6056-260  
Keith R. McCrac :  
Serial No.: 09/461,061 : Group Art Unit: 1653  
Filing Date: December 15, 1999 : Examiner: Hope A. Robinson  
For: **INHIBITION OF ANGIOGENESIS** :  
**BY HIGH MOLECULAR WEIGHT** :  
**KININOGEN DOMAIN 3** :  
**PEPTIDE ANALOGS** :

**PROPOSED ISSUES FOR THE INTERVIEW**

This is in response to Examiner's Robinson request for a written agenda to disclose outstanding issues that would be discussed in the upcoming interview with Examiner Robinson and supervisory Examiner Low.

The main issue in this case is: "what is the subject of the transitional word "comprising" in the preamble of Claim 1?" In other words, "whether the transitional word "comprising" in the preamble of Claim 1 defines the scope of the peptide or the pharmaceutical composition?" The Examiner believes that the transitional word "comprising" in the preamble of Claim 1 defines the scope of the peptide. Applicant respectfully disagrees.

Claim 1 recites:

1. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a compound of the formula X1-SEQ ID NO:1-X2 wherein

X1 is from zero to twelve amino acids, and

X2 is from zero to twelve amino acids.

In re: Patent application of Keith R. McCrae  
Serial No.:09/461,061

Attorney Docket No.: 6056-260  
147539-35926

Applicant respectfully submits that, as it is evident from the language of Claim 1, the transitional word "comprising" clearly defines the scope of the pharmaceutical composition with respect to the elements such as a pharmaceutically acceptable carrier and links the components of the claim. The word "comprising" opens the claimed composition to additional elements that may be included in the pharmaceutical composition and does not change the scope of the claimed fixed-formula compound contained within the composition.

Indeed, as it is amply evident from a reading of Claim 1, the peptide of the pharmaceutical composition claimed is of a fixed length (8 to 32 amino acid long) and has specific formula of X1-SEQ ID NO:1-X2, wherein X1 and X2 are each from zero to twelve amino acids. SEQ ID NO:1 is Asn-Asn-Ala-Thr-Phe-Tyr-Phe-Lys, which corresponds to a portion of human kininogen (HK) domain 3. Assuming that X1 and X2 are each zero to twelve amino acids flanking SEQ ID NO:1, the shortest claimed peptide is 8 amino acids long, and the largest claimed peptide is 32-amino acids long.

Relying on the erroneous interpretation of the subject defined by the transitional word "comprising", as allegedly defining the peptide, the Examiner rejects Claims 1-7 as being anticipated by Auerswald. The rejection alleges that although the sequences disclosed by Auerswald exceed 12 amino acid residues, the claims recite open language such as "comprising" and "has". Thus, the rejection concludes that the reference sequence is identical to the claimed sequences. Applicant respectfully disagrees.


Applicant respectfully submits that the word "has" does not appear in Claim 1 and, for the reasons stated above, Auerswald's peptide is not the same as the claimed peptide. Auerswald discloses a 125-amino acid peptide corresponding to HK peptide, which peptide is about four times larger than the claimed peptide.

In re: Patent application of Keith R. McCrae  
Serial No.:09/461,061

Attorney Docket No.: 6056-260  
147539-35926

Accordingly, Auerswald's peptide does not anticipate the claimed peptide.

Respectfully submitted,

Keith R. McCrae  
  
BY:

HOURI KHALILIAN  
Registration NO. 39,546  
DRINKER BIDDLE & REATH LLP  
Suite 1100  
1500 K Street, N.W.  
Washington, DC 20005-1209  
Bus. (202) 354-1341  
Fax (202) 842-8465

for

DANIEL A. MONACO  
Registration No. 30,480  
DRINKER, BIDDLE & REATH, LLP.  
One Logan Square  
18<sup>th</sup> and Cherry Streets  
Philadelphia, PA 19103  
(215) 988-3312 ph.  
(215) 988-2757 fax

*Attorneys for Applicant*